Johnson & Johnson’s Rybrevant is currently approved for a tiny non-small cell lung cancer (NSCLC) niche. | Johnson & Johnson’s Rybrevant is currently approved…
Pierre Fabre is paying Scorpion Therapeutics $65 million to begin a partnership on clinical development and potential commercialization of two targeted therapies for non-small cell lung cancer. The Scorpion drugs could have safety advantages over approved Johnson & Johnson and Takeda therapies that address the same rare genetic signature.
Seagen’s cancer drug research and collaborations have focused on the development of antibody drug conjugates. By licensing rights to a preclinical Lava Therapeutics asset, Seagen gets a shot to develop a different kind of antibody therapy that could compete against approved products from Johnson & Johnson and Takeda Pharmaceutical.